Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members
Open accessThe DOI matches its Crossref record; 90 of the 91 references it cites were found in a registry or an index; 19 of the 58 sources its claims cite were checked for support.
Abstract
We examined the role of hepatic heparan sulfate in triglyceride-rich lipoprotein metabolism by inactivating the biosynthetic gene GlcNAc N-deacetylase/N-sulfotransferase 1 (Ndst1) in hepatocytes using the Cre-loxP system, which resulted in an approximately 50% reduction in sulfation of liver heparan sulfate. Mice were viable and healthy, but they accumulated triglyceride-rich lipoprotein particles containing apoB-100, apoB-48, apoE, and apoCI-IV. Compounding the mutation with LDL receptor deficiency caused enhanced accumulation of both cholesterol- and triglyceride-rich particles compared with mice lacking only LDL receptors, suggesting that heparan sulfate participates in the clearance of cholesterol-rich lipoproteins as well. Mutant mice synthesized VLDL normally but showed reduced plasma clearance of human VLDL and a corresponding reduction in hepatic VLDL uptake. Retinyl ester excursion studies revealed that clearance of intestinally derived lipoproteins also depended on hepatocyte heparan sulfate. These findings show that under normal physiological conditions, hepatic heparan sulfate proteoglycans play a crucial role in the clearance of both intestinally derived and hepatic lipoprotein particles.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 1 Not valid · 22 Not checked · 102 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Total plasma cholesterol was not affected (80.1 ± 10.1 mg/dl versus 81.4 ± 9.1; n = 20; P = 0.68) (Figure 2B), which contrasts the phenotype of LDLR and LRP mutant mice (15,49).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Ndst1 f/f AlbCre + mice accumulate TRLs.
What the sources say
- Not checked — no full text of the sourcecites [15] Rohlmann, A., Gotthardt, M., Hammer, R.E., and Herz, J. 1998. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J. Clin. Invest. 101:689-695. source
- Supportedcites [49] Ishibashi, S., et al. 1993. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene deliv- ery. J. Clin. Invest. 92:883-893. source
The citation supports the contrast with LDLR-mutant mice, not the citing authors’ 80.1 versus 81.4 mg/dl result. In the Disrupted Allele Wildtype Allele section (Table I; page not provided), the source reports that LDLR-mutant mice have elevated total plasma cholesterol compared with wild-type littermates. (LLM, conf=0.90)
plainn = 20- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The 2-O-sulfation of uronic acids (ΔUA2S-GlcNS and ΔUA2S-GlcNS6S) showed a larger decrease (15% in controls to 3% in the mutant), consistent with previous analyses of HS from mice containing systemic inactivation of Ndst1 (43,44).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Hepatocyte-specific Ndst1 gene disruption alters HS synthesis in liver.
What the sources say
- Supportedcites [43] Grobe, K., et al. 2005. Cerebral hypoplasia and cra- niofacial defects in mice lacking heparan sulfate Ndst1 gene function. Development. 132:3777-3786. source
The citation supports the stated consistency with earlier Ndst1 analyses, not the citing study’s exact 15%-to-3% figures. The source’s Results and Table 1 report a marked decrease in 2-O-sulfated disaccharides in Ndst1 mutant embryos, from 9.7% in wild type to 3.8% in mutants. (LLM, conf=0.92)
- Partly supportedcites [44] Ledin, J., et al. 2004. Heparan sulfate structure in mice with genetically modified heparan sulfate production. J. Biol. Chem. 279:42732-42741. sourceExperimental — accuracy not yet measured
The Results (page unavailable; Table II and Fig. 6A) report that all species of 2-O-sulfated disaccharides decreased in NDST-1-deficient tissues, supporting the direction of the claim. The passages do not give the stated change from 15% in controls to 3% in the mutant, so that magnitude is not verified by our copy. (LLM, conf=0.83)
plainstates a causen = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several rare apoE alleles exhibit reduced binding to HS and cause severe hyperlipoproteinemia (38,39), and mice bearing Lpl defective in HS binding fail to traffic lipids to tissues properly (40).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Introduction
What the sources say
- Partly supportedcites [38] Mann, W.A., et al. 1995. Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu). J. Clin. Invest. 96:1100-1107. sourceExperimental — accuracy not yet measured
The Results report that apoE-1 (Lys146→Glu) bound heparin at 10% of the apoE-3 level, and the Abstract associates this mutant with type III hyperlipoproteinemia. The Discussion uses heparin as a model for cell-surface proteoglycans, but the paper does not directly show reduced HS binding or establish that several rare alleles cause severe hyperlipoproteinemia. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [39] Mann, W.A., et al. 1995. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associ- ated type III hyperlipoproteinemia. J. Lipid Res. 36:517-525. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Several rare apoE alleles exhibit reduced binding to HS and cause severe hyperlipoproteinemia (38,39), and mice bearing Lpl defective in HS binding fail to traffic lipids to tissues properly (40).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Introduction
What the sources say
- Supportedcites [40] Lutz, E.P., et al. 2001. Heparin-binding defective lipoprotein lipase is unstable and causes abnor- malities in lipid delivery to tissues. J. Clin. Invest. 107:1183-1192. source
The Abstract reports that mice expressing LpL with reduced heparin binding had defective targeting of lipids to tissues, with decreased uptake in muscle and increased uptake in kidneys. The Discussion likewise reports altered tissue lipid uptake compared with mice expressing nonmutated LpL. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, clearance of TRLs occurs normally in humans, WHHL rabbits, and mice deficient in LDLR (11)(12)(13).”
§ Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members > Introduction
What the sources say
- Supportedcites [11] Rubinsztein, D.C., et al. 1990. Chylomicron rem- nant clearance from the plasma is normal in famil- ial hypercholesterolemic homozygotes with defined receptor defects. J. Clin. Invest. 86:1306-1312. source
The Discussion (p. 1311) reports normal chylomicron-remnant clearance in human familial hypercholesterolemia subjects with varying degrees of LDL-receptor deficiency. In this three-citation sentence, that human finding is the part supported by this source; the rabbit and mouse findings are not attributed to it individually. (LLM, conf=0.92)
- Supportedcites [12] Kita, T., et al. 1982. Hepatic uptake of chylomicron remnants in WHHL rabbits: a mechanism geneti- cally distinct from the low density lipoprotein receptor. Proc. Natl. Acad. Sci. U. S. A. 79:3623-3627. source
The indexed paper reports that LDL-receptor-deficient WHHL rabbits cleared chylomicrons from plasma at a normal rate, with radiolabeled components removed at comparable rates in WHHL and normal rabbits (section and page not supplied). This paper supports the WHHL-rabbit portion of the sentence; the human and mouse portions have separate citations. (LLM, conf=0.93)
- Partly supportedcites [13] Ishibashi, S., et al. 1996. Role of the low den- sity lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quan- titative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J. Biol. Chem. 271:22422-22427. sourceExperimental — accuracy not yet measured
The Introduction reports little detectable remnant accumulation in LDLR-deficient humans and rabbits, and the Results report prompt clearance of injected remnants in LDLR-deficient mice. But the Results also show a fourfold larger retinyl-ester excursion in those mice after a fat load, so the unqualified claim of normal clearance in mice overstates the paper's findings. The passages supplied do not include page numbers. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
75 more claims · 4 with their cited sources checked
Create a free account to see all 139 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 23
- It may state two separate claims as one. 39
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TRLs arising from LPL-mediated lipolysis are cleared by multiple hepatic receptors, including LDL receptor (LDLR), LDLR-related protein 1 (LRP1), and syndecan-1 (SDC), the predominant hepatic heparin sulfate proteoglycan (HSPG) (Bishop et al., 2008; Foley et al., 2013; MacArthur et al., 2007; Stanford et al., 2009).”
From γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor (2018) · cites this paper as MacArthur et al., 2007
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The fact that both Ldlr–/– and Sdc1–/– mice both accumulate plasma triglycerides”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“heparan sulfate proteoglycans in the liver space of Disse mediate clearance of triglyceride-rich lipoproteins independently of the well-known LDL receptor family members (954 -955).”
From Biological roles of glycans (2017) · cites this paper as [954]
The cited source says what the claim attributes to it.
In the citing paper
“Thus, we believe that the genetic data presented here and previously (9), coupled with numerous cell culture studies by other groups over the years (13–19, 21), argue for independent action of proteoglycans in the hepatic”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“However, we showed previously that compounding Ldlr–/– with Ndst1f/fAlbCre+ mice causes an additive accumulation of plasma triglycerides and prolonged the delay in postprandial clearance manifested by each individual mutant (9).”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [9]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
A modified uronic acid carbazole reaction
Bitter, T., & Muir, H. M. (1962) · Analytical Biochemistry · doi:10.1016/0003-2697(62)90095-7 · Cited by 6,274
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Functions of Cell Surface Heparan Sulfate Proteoglycans
Bernfield, M., Götte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J., & Zako, M. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.729 · Cited by 2,688
An Automated Multidimensional Protein Identification Technology for Shotgun Proteomics
Wolters, D. A., Washburn, M. P., & Yates, J. R. (2001) · Analytical Chemistry · doi:10.1021/ac010617e · Cited by 1,819
Order Out of Chaos: Assembly of Ligand Binding Sites in Heparan Sulfate
Esko, J. D., & Selleck, S. B. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.110601.135458 · Cited by 1,495
Self-citationIshibashi, S., Brown, M. S., Goldstein, J. L., Gerard, R. D., Hammer, R. E., & Herz, J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116663 · Cited by 1,354
Brodie, S. E. (1996) · Survey of Ophthalmology · doi:10.1016/s0039-6257(96)80075-0 · Cited by 745
Mahley, R. W., & Ji, Z.-S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33334-4 · Cited by 693
(1998) · Elsevier eBooks · doi:10.1016/b978-0-12-186060-8.x5000-1 · Cited by 508
Hepatic uptake of chylomicron remnants
Cooper, A. D. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34932-4 · Cited by 499
Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme
Forsberg, E., Pejler, G., Ringvall, M., Lunderius, C., Tomasini-Johansson, B., Kusche-Gullberg, M., Eriksson, I., Ledin, J., Hellman, L., & Kjellén, L. (1999) · Nature · doi:10.1038/23488 · Cited by 481
Guimond, S., Maccarana, M., Olwin, B. B., Lindahl, U., & Rapraeger, A. C. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80471-2 · Cited by 481
Rohlmann, A., Gotthardt, M., Hammer, R. E., & Herz, J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1240 · Cited by 455
Mammalian Brain Morphogenesis and Midline Axon Guidance Require Heparan Sulfate
Inatani, M., Irie, F., Plump, A. S., Tessier-Lavigne, M., & Yamaguchi, Y. (2003) · Science · doi:10.1126/science.1090497 · Cited by 431
Heparin is essential for the storage of specific granule proteases in mast cells
Humphries, D. E., Wong, G. W., Friend, D. S., Gurish, M. F., Qiu, W.-T., Huang, C., Sharpe, A. H., & Stevens, R. L. (1999) · Nature · doi:10.1038/23481 · Cited by 428
Wang, L., Fuster, M., Sriramarao, P., & Esko, J. D. (2005) · Nature Immunology · doi:10.1038/ni1233 · Cited by 413
Self-citationPitas, R. E., Innerarity, T. L., Weinstein, J. N., & Mahley, R. W. (1981) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.1.3.177 · Cited by 388
DNA excision in liver by an albumin-Cre transgene occurs progressively with age
Postic, C., & Magnuson, M. A. (2000) · genesis · doi:10.1002/(sici)1526-968x(200002)26:2<149::aid-gene16>3.0.co;2-v · Cited by 369
Fujino, T., Asaba, H., Kang, M.-J., Ikeda, Y., Sone, H., Takada, S., Kim, D.-H., Ioka, R. X., Ono, M., Tomoyori, H., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0133792100 · Cited by 336
Ji, Z. S., Brecht, W. J., Miranda, R. D., Hussain, M. M., Innerarity, T. L., & Mahley, R. W. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82186-x · Cited by 305
Heparan sulfate proteoglycan as a plasma membrane carrier
Belting, M. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00031-8 · Cited by 273
Weinstock, P. H., Bisgaier, C. L., Aalto-Setälä, K., Radner, H., Ramakrishnan, R., Levak-Frank, S., Essenburg, A. D., Zechner, R., & Breslow, J. L. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118319 · Cited by 254
Heparan Sulfate Structure in Mice with Genetically Modified Heparan Sulfate Production
Ledin, J., Staatz, W., Li, J.-P., Götte, M., Selleck, S., Kjellén, L., & Spillmann, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405382200 · Cited by 230
Ringvall, M., Ledin, J., Holmborn, K., van Kuppevelt, T., Ellin, F., Eriksson, I., Olofsson, A.-M., Kjellén, L., & Forsberg, E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000359200 · Cited by 217
Fuki, I. V., Kuhn, K. M., Lomazov, I. R., Rothman, V. L., Tuszynski, G. P., Iozzo, R. V., Swenson, T. L., Fisher, E. A., & Williams, K. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119685 · Cited by 213
Hepatic Lipase, Lipoprotein Metabolism, and Atherogenesis
Santamarina-Fojo, S., González-Navarro, H., Freeman, L., Wagner, E., & Nong, Z. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000140818.00570.2d · Cited by 211
Williams, K. J., Fless, G. M., Petrie, K. A., Snyder, M. L., Brocia, R. W., & Swenson, T. L. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42208-9 · Cited by 205
Liver heparan sulfate structure. A novel molecular design
Lyon, M., Deakin, J. A., & Gallagher, J. T. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)78112-5 · Cited by 202
Mild Dyslipidemia in Mice following Targeted Inactivation of the Hepatic Lipase Gene
Homanics, G. E., de Silva, H. V., Osada, J., Zhang, S. H., Wong, H., Borensztajn, J., & Maeda, N. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.7.2974 · Cited by 197
Horton, J. D., Shimano, H., Hamilton, R. L., Brown, M. S., & Goldstein, J. L. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6246 · Cited by 190
Cerebral hypoplasia and craniofacial defects in mice lacking heparan sulfate Ndst1 gene function
Grobe, K., Inatani, M., Pallerla, S. R., Castagnola, J., Yamaguchi, Y., & Esko, J. D. (2005) · Development · doi:10.1242/dev.01935 · Cited by 173
Self-citationKita, T., Goldstein, J. L., Brown, M. S., Watanabe, Y., Hornick, C. A., & Havel, R. J. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.11.3623 · Cited by 167
Fan, G., Xiao, L., Cheng, L., Wang, X., Sun, B., & Hu, G. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01111-x · Cited by 165
[13] Isolation and characterization of apolipoprotein E
Rall, S. C., Weisgraber, K. H., & Mahley, R. W. (1986) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(86)28073-8 · Cited by 157
Sustained somatic gene inactivation by viral transfer of Cre recombinase
Rohlmann, A., Gotthardt, M., Willnow, T., Hammer, R., & Herz, J. (1996) · Nature Biotechnology · doi:10.1038/nbt1196-1562 · Cited by 157
Ji, Z. S., Fazio, S., & Mahley, R. W. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36849-7 · Cited by 138
Ji, Z. S., Lauer, S. J., Fazio, S., Bensadoun, A., Taylor, J. M., & Mahley, R. W. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36850-3 · Cited by 137
Self-citationPreparation, characterization, and measurement of hepatic lipase
Ehnholm, C., & Kuusi, T. (1986) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(86)29101-6 · Cited by 134
Apolipoprotein E localization in rat hepatocytes by immunogold labeling of cryothin sections
Hamilton, R., Wong, J., Guo, L., Krisans, S., & Havel, R. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42343-0 · Cited by 129
Ji, Z.-S., Dichek, H. L., Miranda, R. D., & Mahley, R. W. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31285 · Cited by 128
Ji, Z. S., & Mahley, R. W. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.12.2025 · Cited by 117
[Structure and metabolism of plasma lipoproteins].
Polonovski, J., & Beucler, I. (1983) · PubMed · Cited by 115
Cell-surface heparan sulfate proteoglycans: dynamic molecules mediating ligand catabolism
Jon Williams, K., & Fuki, I. V. (1997) · Current Opinion in Lipidology · doi:10.1097/00041433-199710000-00003 · Cited by 113
New Insights into the Heparan Sulfate Proteoglycan-binding Activity of Apolipoprotein E
Libeu, C. P., Lund-Katz, S., Phillips, M. C., Wehrli, S., Hernáiz, M. J., Capila, I., Linhardt, R. J., Raffaı̈, R. L., Newhouse, Y. M., Zhou, F., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104746200 · Cited by 113
Magoori, K., Kang, M.-J., Ito, M. R., Kakuuchi, H., Ioka, R. X., Kamataki, A., Kim, D.-H., Asaba, H., Iwasaki, S., Takei, Y. A., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211987200 · Cited by 111
[7] Density gradient ultracentrifugation of serum lipoproteins in a swinging bucket rotor
Kelley, J., & Kruski, A. W. (1986) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(86)28067-2 · Cited by 110
Role of the Low Density Lipoprotein (LDL) Receptor Pathway in the Metabolism of Chylomicron Remnants
Ishibashi, S., Perrey, S., Chen, Z., Osuga, J.-I., Shimada, M., Ohashi, K., Harada, K., Yazaki, Y., & Yamada, N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.37.22422 · Cited by 106
Ji, Z. S., Sanan, D. A., & Mahley, R. W. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39892-8 · Cited by 106
Rubinsztein, D. C., Cohen, J. C., Berger, G. M., van der Westhuyzen, D. R., Coetzee, G. A., & Gevers, W. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114839 · Cited by 101
Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk
Otarod, J. K., & Goldberg, I. J. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0043-4 · Cited by 99
Interaction of the N-Terminal Domain of Apolipoprotein E4 with Heparin
Dong, J., Peters-Libeu, C. A., Weisgraber, K. H., Segelke, B. W., Rupp, B., Capila, I., Hernáiz, M. J., LeBrun, L. A., & Linhardt, R. J. (2001) · Biochemistry · doi:10.1021/bi002417n · Cited by 99
Perlecan Heparan Sulfate Proteoglycan
Fuki, I. V., Iozzo, R. V., & Williams, K. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909173199 · Cited by 95
Preparation, characterization, and measurement of lipoprotein lipase
Iverius, P., & Östlund‐Lindqvist, A. (1986) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(86)29099-0 · Cited by 92
Parthasarathy, N., Goldberg, I. J., Sivaram, P., Mulloy, B., Flory, D. M., & Wagner, W. D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31802-1 · Cited by 90
Ebara, T., Conde, K., Kako, Y., Liu, Y., Xu, Y., Ramakrishnan, R., Goldberg, I. J., & Shachter, N. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8283 · Cited by 86
The unstirred water layer as a site of control of apolipoprotein B secretion.
Williams, K. J., Brocia, R. W., & Fisher, E. A. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44822-8 · Cited by 81
Grobe, K., & Esko, J. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111904200 · Cited by 81
Self-citationAl-Haideri, M., Goldberg, I. J., Galeano, N. F., Gleeson, A., Vogel, T., Gorecki, M., Sturley, S. L., & Deckelbaum, R. J. (1997) · Biochemistry · doi:10.1021/bi9631024 · Cited by 76
Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B.
Young, S. G., Smith, R. S., Hogle, D. M., Curtiss, L. K., & Witztum, J. L. (1986) · Clinical Chemistry · doi:10.1093/clinchem/32.8.1484 · Cited by 75
Self-citationMortimer, B.-C., Beveridge, D. J., Martins, I. J., & Redgrave, T. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.48.28767 · Cited by 74
Hepatic lipase is abundant on both hepatocyte and endothelial cell surfaces in the liver
Sanan, D. A., Fan, J., Bensadoun, A., & Taylor, J. M. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37224-2 · Cited by 72
Self-citationHeparin decreases the degradation rate of lipoprotein lipase in adipocytes.
Cupp, M., Bensadoun, A., & Melford, K. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45581-0 · Cited by 69
Self-citationWilsie, L. C., & Orlando, R. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208786200 · Cited by 68
Reduced Sulfation of Liver Heparan Sulfate in Experimentally Diabetic Rats
Kjellén, L., Bielefeld, D., & Hook, M. (1983) · Diabetes · doi:10.2337/diab.32.4.337 · Cited by 67
Identification and characterization of the endothelial cell surface lipoprotein lipase receptor.
Saxena, U., Klein, M. G., & Goldberg, I. J. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)47402-4 · Cited by 65
Structural characterization of human liver heparan sulfate
Vongchan, P., Warda, M., Toyoda, H., Toida, T., Marks, R. M., & Linhardt, R. J. (2005) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2004.09.007 · Cited by 65
Hepatic Catabolism of Remnant Lipoproteins: Where the Action Is
Havel, R. J., & Hamilton, R. L. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000115382.53810.24 · Cited by 58
Genetics and molecular biology of hepatic lipase
Bensadoun, A., & Berryman, D. E. (1996) · Current Opinion in Lipidology · doi:10.1097/00041433-199604000-00005 · Cited by 54
Self-citationToyoda, H., Nagashima, T., Hirata, R., Toida, T., & Imanari, T. (1997) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(97)00478-7 · Cited by 52
Yanagishita, M. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50119-3 · Cited by 51
Lutz, E. P., Merkel, M., Kako, Y., Melford, K., Radner, H., Breslow, J. L., Bensadoun, A., & Goldberg, I. J. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11774 · Cited by 48
Self-citationOlsson, U., Egnell, A.-C., Lee, M. R., Lundén, G. O., Lorentzon, M., Salmivirta, M., Bondjers, G., & Camejo, G. (2001) · Diabetes · doi:10.2337/diabetes.50.9.2126 · Cited by 44
Unger, E., Pettersson, I., Eriksson, U. J., Lindahl, U., & Kjellén, L. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)31496-0 · Cited by 43
Zeng, B.-J., Mortimer, B.-C., Martins, I. J., Seydel, U., & Redgrave, T. G. (1998) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32571-2 · Cited by 43
Mann, W. A., Meyer, N., Weber, W., Meyer, S., Greten, H., & Beisiegel, U. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39885-0 · Cited by 37
Windler, E., Greeve, J., Robenek, H., Rinninger, F., Greten, H., & Jäckle, S. (1996) · Hepatology · doi:10.1002/hep.510240210 · Cited by 35
Inaba, T., Ishibashi, S., Harada, K., Ohsuga, J.-I., Ohashi, K., Yagyu, H., Yazaki, Y., Higashiyama, S., Kawata, S., Matsuzawa, Y., et al. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.40.24413 · Cited by 35
Cell Surface Heparan Sulfate Promotes Replication of Toxoplasma gondii
Bishop, J. R., Crawford, B. E., & Esko, J. D. (2005) · Infection and Immunity · doi:10.1128/iai.73.9.5395-5401.2005 · Cited by 33
Self-citationLoss of Heparan N-Sulfotransferase in Diabetic Liver
Williams, K. J., Liu, M.-L., Zhu, Y., Xu, X., Davidson, W. R., McCue, P., & Sharma, K. (2005) · Diabetes · doi:10.2337/diabetes.54.4.1116 · Cited by 31
Nitrocellulose Filter Binding to Assess Binding of Glycosaminoglycans to Proteins
Kreuger, J., Lindahl, U., & Jemth, P. (2003) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(03)01062-0 · Cited by 28
Mann, W. A., Lohse, P., Gregg, R. E., Ronan, R., Hoeg, J. M., Zech, L. A., & Brewer, H. B. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118096 · Cited by 28
Enzyme-linked immunosorbent assay for rat hepatic triglyceride lipase.
Cisar, L. A., & Bensadoun, A. (1985) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34381-9 · Cited by 26
Self-citationLipoprotein lipase in liver. Release by heparin and immunocytochemical localization
Vilaró, S., Ramírez, I., Bengtsson-Olivecrona, G., Olivecrona, T., & Llobera, M. (1988) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(88)90021-5 · Cited by 25
Spillmann, D., Lookene, A., & Olivecrona, G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604702200 · Cited by 24
Sendak, R. A., Berryman, D. E., Gellman, G., Melford, K., & Bensadoun, A. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32060-5 · Cited by 24
Self-citationHirano, T., Takahashi, T., Saito, S., Tajima, H., Ebara, T., & Adachi, M. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.4.e665 · Cited by 19
Mapping the heparin-binding domain of human hepatic lipase
Yu, W., & Hill, J. S. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.02.175 · Cited by 15
Williams, C. M. (1997) · Current Opinion in Lipidology · doi:10.1097/00041433-199706000-00013 · Cited by 13
Research works printed but not linked: 2
- Belting, M. 2003. Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem. Sci. 28:145-151. · DOI · Paper page
- Iverius, P., and Ostlund-Lindqvist, A. 1986. Prepa- ration, characterization, and measurement of lipo- protein lipase. In Methods in enzymology. J.J. Albers and J.P. Segrest, editors. Academic Press. Orlando, Florida, USA. 691-704.
Cited by
MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., & Remaley, A. T. (2011) · Nature Cell Biology · doi:10.1038/ncb2210 · Cited by 2,741
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“For example heparan sulfate proteoglycans in the liver space of Disse mediate clearance of triglyceride-rich lipoproteins independently of the well-known LDL receptor family members (954, 955).”
BackgroundHeparan sulphate proteoglycans fine-tune mammalian physiology
Bishop, J. R., Schuksz, M., & Esko, J. D. (2007) · Nature · doi:10.1038/nature05817 · Cited by 1,631
Self-citationSarrazin, S., Lamanna, W. C., & Esko, J. D. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004952 · Cited by 1,516
“Altering the structure of HS by selective inactivation of sulfotransferases in hepatocytes led to the same phenotype and showed that the HS chains on syndecan-1 represent the binding site for the lipoproteins (MacArthur et al. 2007; Stanford et al. 2010).”
BackgroundSelf-citationTabas, I., Williams, K. J., & Borén, J. (2007) · Circulation · doi:10.1161/circulationaha.106.676890 · Cited by 1,399
Metadata
- Authors
- MacArthur, J. M., Bishop, J. R., Stanford, K. I., Wang, L., Bensadoun, A., Witztum, J. L., & Esko, J. D.
- Affiliations
- University of California San Diego (US)
- Cornell University (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2007-01-02
- Volume
- 117
- Issue
- 1
- Pages
- 153-164
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1716206
- OpenAlex
- W2157280645
- Cited by
- 216
- References
- 91
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 4 · 2023: 5 · 2022: 3 · 2021: 9 · 2020: 4 · 2019: 7 · 2018: 8 · 2017: 9 · 2016: 14 · 2015: 12 · 2014: 17 · 2013: 14 · 2012: 11
- FWCI
- 17.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Foundation
- National Institutes of Health (HL57345, GM33063)
- University of California, San Diego
- National Heart, Lung, and Blood Institute (HL 57345, P50HL056989, P01HL057345, HL-56989)
- National Institute of General Medical Sciences (R01GM033063, R37GM033063, GM-33063)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Keywords
- heparan sulfate proteoglycans, triglyceride-rich lipoproteins, lipoprotein clearance, NDST1, LDL receptor, hepatic lipoprotein metabolism, apolipoproteins
- MeSH terms
- Apolipoproteins E, Humans, Lipoproteins, Liver, Receptors, LDL, Triglycerides, Hypertriglyceridemia, Fibroblast Growth Factor 2, Heparan Sulfate Proteoglycans, Hepatocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.